Contact Us
Drug Search Results
More Filters [+]

Valspodar

Alternative Names: valspodar, psc-833, psc833, psc 833
Latest Update: 2023-12-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: P-gp Inhibitor

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: National Cancer Institute (NCI)
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Valspodar

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Acute Eosinophilic Leukemia|Acute Erythroblastic Leukemia|Acute Myeloid Leukemia|Plasmacytoma|Multiple Myeloma|Acute Monocytic Leukemia|Acute Megakaryoblastic Leukemia|Acute Myelomonocytic Leukemia|Myelodysplastic Syndrome|Hypereosinophilic Syndrome|Acute Basophilic Leukemia|Chronic Myeloid Leukemia|Preleukemia|Chronic Myelomonocytic Leukemia

Phase 2: Breast Cancer|Leukemia|Acute Myeloid Leukemia

Phase 1: Renal Cell Carcinoma|Lymphoma|Leukemia|Breast Cancer|Ovarian Cancer|Sarcoma, Kaposi|Kidney Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCI-2012-01835

P1

Completed

Leukemia

2006-03-01

NCI-2012-02824

P3

Completed

Chronic Myelomonocytic Leukemia|Acute Basophilic Leukemia|Hypereosinophilic Syndrome|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Acute Megakaryoblastic Leukemia|Acute Eosinophilic Leukemia|Acute Erythroblastic Leukemia|Preleukemia|Chronic Myeloid Leukemia|Acute Myelomonocytic Leukemia|Acute Monocytic Leukemia

2005-06-01

CDR0000065011

P2

Completed

Breast Cancer

2003-11-01

CDR0000065333

P2

Completed

Leukemia

2003-11-01

Recent News Events

Date

Type

Title

12/01/2023

PubMed

 Development and Functional Evaluation of MDR1-expressing Microvascular Endothelial-like Cells Derived from Human iPS Cells as an In vitro Blood-brain Barrier Model.

12/01/2023

PubMed

 Comparative study on ABCB1-dependent efflux of anthracyclines and their metabolites: consequences for cancer resistance.

08/01/2023

PubMed

 Understanding the Mechanism and Extent of Transplacental Transfer of (-)-∆9 -Tetrahydrocannabinol (THC) in the Perfused Human Placenta to Predict In Vivo Fetal THC Exposure.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions